The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b

被引：107
作者：
Rice, GPA
Paszner, B
Oger, J
Lesaux, J
Paty, D
Ebers, G
机构：
[1] London MS Clin, London, ON N6A 5A5, Canada
[2] Univ British Columbia, MS Clin, Vancouver, BC V5Z 1M9, Canada
来源：
NEUROLOGY | 1999年 / 52卷 / 06期
关键词：
D O I：
10.1212/WNL.52.6.1277
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The fate of the neutralizing antibody (NAB) in MS patients treated with interferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon beta-1b. NAB were measured with the myxovirus protein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.
引用
收藏
页码：1277 / 1279
页数：3
相关论文
共 10 条
  • [1] DUQUETTE P, 1995, NEUROLOGY, V45, P1277
  • [2] Duquette P, 1996, NEUROLOGY, V47, P889
  • [3] A novel sensitive and selective bioassay for human type I interferons
    Files, JG
    Gray, JL
    Do, LT
    Foley, WP
    Gabe, JD
    Nestaas, E
    Pungor, E
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1998, 18 (12) : 1019 - 1024
  • [4] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis
    Jacobs, LD
    Cookfair, DL
    Rudick, RA
    Herndon, RM
    Richert, JR
    Salazar, AM
    Fischer, JS
    Goodkin, DE
    Granger, CV
    Simon, JH
    Alam, JJ
    Bartoszak, DM
    Bourdette, DN
    Braiman, J
    Brownscheidle, CM
    Coats, ME
    Cohan, SL
    Dougherty, DS
    Kinkel, RP
    Mass, MK
    Munschauer, FE
    Priore, RL
    Pullicino, PM
    Scherokman, BJ
    WeinstockGuttman, B
    Whitman, RH
    Baird, WC
    Fillmore, M
    Bona, LM
    ColonRuiz, ME
    Nadine, BS
    Donovan, A
    Bennett, S
    Kieffer, YM
    Umhauer, MA
    Miller, CE
    Kilic, AK
    Sargent, EL
    Schachter, M
    Shucard, DW
    Weider, V
    Catalano, BA
    Cervi, JM
    Czekay, C
    Farrell, JL
    Filippini, JS
    Matyas, RC
    Michienzi, KE
    Ito, M
    OMalley, JA
    [J]. ANNALS OF NEUROLOGY, 1996, 39 (03) : 285 - 294
  • [5] Oger JJ, 1998, NEUROLOGY, V50, pA342
  • [6] QUANTITATION OF INTERFERON-INDUCED MX-PROTEIN IN WHOLE-BLOOD LYSATES BY AN IMMUNOCHEMILUMINESCENT ASSAY - ELIMINATION OF PROTEASE ACTIVITY OF CELL LYSATES IN-TOTO
    OH, SK
    LUHOWSKYJ, S
    WITT, P
    RITCH, P
    REITSMA, D
    TOWBIN, H
    HORISBERGER, M
    VONWUSSOW, P
    BLUESTEIN, B
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1994, 176 (01) : 79 - 91
  • [7] Guidelines for physicians with patients on IFN beta-1b: The use of an assay for neutralizing antibodies (NAB)
    Paty, DW
    Goodkin, D
    Thompson, A
    Rice, G
    [J]. NEUROLOGY, 1996, 47 (04) : 865 - 866
  • [8] RICE GPA, 1997, MULT SCLER, V3, P84
  • [9] Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
    Rudick, RA
    Simonian, NA
    Alam, JA
    Campion, M
    Scaramucci, JO
    Jones, W
    Coats, ME
    Goodkin, DE
    Weinstock-Guttman, B
    Herndon, RM
    Mass, MK
    Richert, JR
    Salazar, AM
    Munschauer, FE
    Cookfair, DL
    Simon, JH
    Jacobs, LD
    [J]. NEUROLOGY, 1998, 50 (05) : 1266 - 1272
  • [10] THE EFFECT OF INTERFERON-BETA ON BLOOD-BRAIN-BARRIER DISRUPTIONS DEMONSTRATED BY CONTRAST-ENHANCED MAGNETIC-RESONANCE-IMAGING IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS
    STONE, LA
    FRANK, JA
    ALBERT, PS
    BASH, C
    SMITH, ME
    MALONI, H
    MCFARLAND, HF
    [J]. ANNALS OF NEUROLOGY, 1995, 37 (05) : 611 - 619
1